首页> 外文期刊>Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation >T Cell and B Cell Immunity can be Reconstituted with Mismatched Hematopoietic Stem Cell Transplantation Without Alkylator Therapy in Artemis-Deficient Mice Using Anti-Natural Killer Cell Antibody and Photochemically Treated Sensitized Donor T Cells
【24h】

T Cell and B Cell Immunity can be Reconstituted with Mismatched Hematopoietic Stem Cell Transplantation Without Alkylator Therapy in Artemis-Deficient Mice Using Anti-Natural Killer Cell Antibody and Photochemically Treated Sensitized Donor T Cells

机译:可以使用抗自然杀伤细胞抗体和光化学处理的敏化供体T细胞,在不使用烷基化剂治疗的青蒿素缺乏小鼠中,通过不匹配的造血干细胞移植重建T细胞和B细胞免疫。

获取原文
获取原文并翻译 | 示例
           

摘要

Children with Artemis-deficient T -B -NK + severe combined immunodeficiency are at high risk for graft rejection from natural killer (NK) cells and toxicity from increased sensitivity to the alkylating agents used in mismatched hematopoietic stem cell transplantation (HSCT). We evaluated the use of a nonalkylating agent regimen before HSCT in Artemis-deficient (mArt -/-) C57Bl/6 (B6) mice to open marrow niches and achieve long-term multilineage engraftment with full T cell and B cell immune reconstitution. We found that partial depletion of both recipient NK cells using anti-NK1.1 monoclonal antibody and donor T cells sensitized to recipient splenocytes was necessary. BALB/c-sensitized T cells (STCs) were photochemically treated (PCT) with psoralen and UVA light to inhibit proliferation, reduce the risk of graft-versus-host disease (GVHD), and target host hematopoietic stem cells (HSCs). A dose of 4 × 10 5 PCT STCs coinjected with 1 × 10 5 lineage-depleted c-kit + BALB/c HSCs resulted in 43.9% ± 3.3% CD4 + and 10.9% ± 1.2% CD8 + donor T cells in blood, 29% ± 7.8% and 21.7% ± 4.0 donor B220 + IgM + in spleen and bone marrow, and 15.0% ± 3.6% donor Gran-1 + cells in bone marrow at 6 months post-HSCT versus 0.02% ± 0.01%, 0.13% ± 0.10%, 0.53% ± 0.16%, 0.49% ± 0.09%, and 0.20% ± 0.06%, respectively, in controls who did not receive PCT STCs. We found that STCs target host HSCs and that PCT STCs are detectable only up to 24 hours after infusion, in contrast to non-photochemically treated STCs, which proliferate resulting in fatal GVHD. Increased mortality in the groups receiving 4-6 × 10 5 PCT STCs was associated with evidence of GVHD, particularly in the recipients of 6 × 10 5 cells. These results demonstrate that blocking NK cell-mediated resistance and making niches in bone marrow are both essential to achieving multilineage engraftment of mismatched donor cells and T cell and B cell reconstitution, even though GVHD is not completely eliminated.
机译:患有Artemis缺陷型T-B -NK +严重的联合免疫缺陷的儿童处于高风险的风险中,因为天然杀伤(NK)细胞会导致移植物排斥,并且由于对错配的造血干细胞移植(HSCT)中使用的烷基化剂的敏感性增加,会引起毒性。我们评估了在Artemis缺陷(mArt-/-)C57Bl / 6(B6)小鼠中HSCT之前非烷基化剂方案的使用,以打开骨髓壁and并实现具有完整T细胞和B细胞免疫重构的长期多系移植。我们发现使用抗NK1.1单克隆抗体和供体T细胞对受体脾细胞致敏的受体NK细胞的部分耗竭是必要的。用补骨脂素和UVA光对BALB / c敏感的T细胞(STC)进行光化学处理(PCT),以抑制增殖,降低移植物抗宿主疾病(GVHD)的风险,并靶向宿主造血干细胞(HSC)。将4×10 5 PCT STC与1×10 5世系耗竭的c-kit + BALB / c HSC一起注射,可产生血液中43.9%±3.3%CD4 +和10.9%±1.2%CD8 +供体T细胞,29 HSCT后6个月,脾脏和骨髓中的供体B220 + IgM +为%±7.8%和21.7%±4.0,HSCT后6个月骨髓中的供体Gran-1 +细胞为15.0%±3.6%,而0.02%±0.01%,0.13%在未接受PCT STC的对照组中,分别为±0.10%,0.53%±0.16%,0.49%±0.09%和0.20%±0.06%。我们发现STC靶向宿主HSC,而PCT STC只能在输注后24小时内检测到,这与未经光化学处理的STC相比会扩散,导致致命的GVHD。接受4-6×10 5个PCT STC的组死亡率增加与GVHD的证据有关,特别是在接受6×10 5个细胞的组中。这些结果表明,即使未完全消除GVHD,阻断NK细胞介导的抗性和在骨髓中形成壁ni对于实现错配供体细胞的多谱系移植以及T细胞和B细胞的重构都是必不可少的。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号